key: cord-0742911-3y2j8bej authors: Palaiodimou, Lina; Stefanou, Maria‐Ioanna; Katsanos, Aristeidis H.; Fragkou, Paraskevi C.; Papadopoulou, Marianna; Moschovos, Christos; Michopoulos, Ioannis; Kokotis, Panagiotis; Bakirtzis, Christos; Naska, Androniki; Vassilakopoulos, Theodoros I.; Chroni, Elisabeth; Tsiodras, Sotirios; Tsivgoulis, Georgios title: Prevalence, clinical characteristics and outcomes of Guillain−Barré syndrome spectrum associated with COVID‐19: A systematic review and meta‐analysis date: 2021-04-28 journal: Eur J Neurol DOI: 10.1111/ene.14860 sha: e6c18175ca7635720c8758b16a940dfb23b2cbfe doc_id: 742911 cord_uid: 3y2j8bej BACKGROUND AND PURPOSE: Mounting evidence supports an association between Guillain−Barré syndrome spectrum (GBSs) and severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) infection. However, GBSs in the setting of coronavirus disease 2019 (COVID‐19) remains poorly characterized, whilst GBSs prevalence amongst COVID‐19 patients has not been previously systematically evaluated using a meta‐analytical approach. METHODS: A systematic review and meta‐analysis of observational cohort and case series studies reporting on the occurrence, clinical characteristics and outcomes of patients with COVID‐19‐associated GBSs was performed. A random‐effects model was used to calculate pooled estimates and odds ratios (ORs) with corresponding 95% confidence intervals (CIs), compared to non‐COVID‐19, contemporary or historical GBSs patients. RESULTS: Eighteen eligible studies (11 cohorts, seven case series) were identified including a total of 136,746 COVID‐19 patients. Amongst COVID‐19 patients, including hospitalized and non‐hospitalized cases, the pooled GBSs prevalence was 0.15‰ (95% CI 0%–0.49‰; I (2) = 96%). Compared with non‐infected contemporary or historical controls, patients with SARS‐CoV‐2 infection had increased odds for demyelinating GBSs subtypes (OR 3.27, 95% CI 1.32%–8.09%; I (2) = 0%). In SARS‐CoV‐2‐infected patients, olfactory or concomitant cranial nerve involvement was noted in 41.4% (95% CI 3.5%–60.4%; I (2) = 46%) and 42.8% (95% CI 32.8%–53%; I (2) = 0%) of the patients, respectively. Clinical outcomes including in‐hospital mortality were comparable between COVID‐19 GBSs patients and non‐infected contemporary or historical GBSs controls. CONCLUSION: GBSs prevalence was estimated at 15 cases per 100,000 SARS‐CoV‐2 infections. COVID‐19 appears to be associated with an increased likelihood of GBSs and with demyelinating GBSs variants in particular. Guillain−Barré syndrome spectrum (GBSs) has been increasingly recognized as a neurological manifestation of coronavirus disease 2019 in patients with severe acute respiratory coronavirus 2 (SARS-CoV-2) infection [1] . Since the first reported GBSs case in January 2020 in a COVID-19 patient from Wuhan [2] , the number of published cases, case series and observational studies postulating a positive correlation and a possible pathogenetic link between SARS-CoV-2 and GBSs has grown exponentially [1, 3, 4] . In contrast, recent epidemiological data have emerged contradicting this hypothesis and demonstrating a reduced GBSs incidence during the COVID-19 pandemic compared to the pre-COVID era amongst the UK population [5] . Guillain−Barré syndrome spectrum comprises a spectrum of acute, immune-mediated polyneuropathies that can be distinguished into different subtypes according to clinical features and electrophysiological findings, such as acute inflammatory demyelinating polyneuropathy (AIDP), acute motor axonal neuropathy (AMAN) [6] and acute motor sensory axonal neuropathy (AMSAN), and encompasses the clinical GBS variants Miller−Fisher syndrome (MFS) and Bickerstaff's brainstem encephalitis [7, 8] . According to epidemiological studies, the overall incidence of GBSs is estimated between 0.8 and 1.9/100,000/year in the general population [9] . Although the epidemiological evidence on post-infectious GBSs is equivocal [9] , approximately two-thirds of total GBSs cases are considered to be related to antecedent infections [10] . Amongst the infectious agents associated with GBSs are bacteria, including Campylobacter jejuni, Mycoplasma pneumoniae and Haemophilus influenzae, and viruses, including cytomegalovirus (CMV), influenza, enteroviruses, Epstein−Barr virus, herpes simplex virus, hepatitis, human immunodeficiency virus and Zika virus [10] [11] [12] . Only for few pathogens, however, including C. jejuni and CMV, has a causal link via 'molecular mimicry' or cross-reactive antibodies against ganglioside epitopes been established, particularly for AMAN, AMSAN and MFS [13] . To date, the pathophysiological mechanisms underlying the neurological manifestations of COVID-19 remain only partially elucidated [11] . Moreover, as the COVID-19 pandemic still progresses, epidemiological associations between GBSs and SARS-CoV-2 remain tentative. The aim of the present systematic review and meta-analysis was to critically appraise the published literature related to GBSs and COVID-19, and to evaluate the prevalence, clinical features and outcomes of GBSs in patients with COVID-19 compared to non-COVID-19 contemporary or historical controls. 95% CI 1.32%-8.09%; I 2 = 0%). In SARS-CoV-2-infected patients, olfactory or concomitant cranial nerve involvement was noted in 41.4% (95% CI 3.5%-60.4%; I 2 = 46%) and 42 .8% (95% CI 32.8%-53%; I 2 = 0%) of the patients, respectively. Clinical outcomes including in-hospital mortality were comparable between COVID-19 GBSs patients and non-infected contemporary or historical GBSs controls. GBSs prevalence was estimated at 15 cases per 100,000 SARS-CoV-2 infections. COVID-19 appears to be associated with an increased likelihood of GBSs and with demyelinating GBSs variants in particular. COVID-19, Guillain−Barré syndrome, acute inflammatory demyelinating polyneuropathy, prevalence, mortality (ii) commentaries, narrative and systematic reviews; (iii) studies with overlapping data; and (iv) studies thematically unrelated to the study objective. An aggregate data meta-analysis was performed including observational cohort studies and case series reporting on the occurrence and clinical features of patients presenting with GBSs in association with COVID-19. The meta-analysis is reported in accordance with the Preferred Reporting Items for Systematic Reviews and Metaanalyses (PRISMA) guidelines [15] and was written according to the Meta-analysis of Observational Studies in Epidemiology (MOOSE) proposal [16] . The pre-specified study protocol has been registered in the International Prospective Register of Ongoing Systematic Reviews PROSPERO (CRD42020227361). Eligible observational cohort studies and case series were subjected to quality control and bias assessment employing the Newcastle− Ottawa Scale and the checklist developed by the US National Heart Lung and Blood Institute for case series studies, respectively [17, 18] . The quality control and bias assessment was conducted independently by three reviewers (LP, MIS, CM), and disagreements were resolved via consensus and discussion with the corresponding author (GT). Our predefined primary outcome measures were twofold: (i) the pooled prevalence rate of GBSs amongst COVID-19 patients; and (ii) GBSs prevalence amongst COVID-19 patients compared to either contemporary or historical non-COVID-19 GBSs controls. As secondary outcomes of interest the rates of (i) clinical improvement, (ii) intensive care unit admission, (iii) mechanical ventilation and (iv) all-cause mortality amongst COVID-19 GBSs patients were further assessed; they were compared to their non-COVID-19 contemporary or historical GBSs counterparts. Finally, potential differences in demographics and clinical GBSs features between groups of patients stratified by COVID-19 status were evaluated. As an additional exploratory analysis, the number of reported to the number of expected GBSs cases were compared between COVID-19 patients, assuming a similar GBSs incidence between SARS-CoV-2 positive patients and the general population. To calculate the total number of reported COVID-19-associated GBSs cases, cohort and case series studies were considered, along with case reports that were identified by the literature search but were excluded from the meta-analysis. After exclusion of possible overlapping data, the reported cases were stratified by country of origin. To estimate the number of expected GBSs cases, the number of patients diagnosed with COVID-19 in each country, as reported in the Coronavirus Resource Center of the Johns Hopkins University and Medicine until 18 December 2020 [19] , was multiplied by the overall incidence of GBS in the general population (1.89/100,000) [9] . The prevalence of GBSs amongst COVID-19 patients was calculated by dividing the number of patients with COVID-19 and GBSs (including all GBS subtypes and variants) by the total number of COVID-19 individuals, after implementation of the variance-stabilizing double arcsine transformation. The random-effects model of meta-analysis (DerSimonian and Laird) [20] was used to calculate the pooled estimates. Pairwise comparisons were conducted between COVID-19 patients with GBSs and controls (GBSs cases without COVID-19) and were reported using odds ratios (ORs) and corresponding 95% confidence intervals (95% CIs). Additionally, all previous analyses were performed after subgroup stratification according to study design (cohort or case series). Heterogeneity between included studies was assessed with the Cochran Q and I 2 statistics. For the qualitative interpretation of heterogeneity, I 2 values of at least 50% were considered to represent substantial heterogeneity, whilst values of at least 75% indicated considerable heterogeneity [21] . The significance level for the Q statistic was set at 0.1, and the equivalent z test for each pooled OR with a two-tailed p value <0.05 was considered as statistically significant. Publication bias across individual studies was assessed when more than four studies were included in each analysis, using both funnel plot inspection and Egger's linear regression test [22] . All statistical analyses were conducted using the OpenMetaAnalyst [23] and Stata Statistical Software Release 13 for Windows (StataCorp LP). The systematic database search yielded a total of 280 and 264 records from the MEDLINE and Scopus databases, respectively ( Figure 1 ). After excluding duplicates and out-of-scope articles, the full text of 104 records that were considered potentially eligible for inclusion were retrieved. After reading the full-text articles, 82 were excluded (Table S1 ). Finally, 18 observational studies (11 cohorts and seven case series) were identified including a total of 136,746 COVID-19 patients that were in line with our predefined inclusion/ exclusion criteria (Table 1 ). The risk of bias in included cohort studies was assessed by the Newcastle−Ottawa scale and is presented in Table S2 [18] . The overall score was 71 of 99 (72%), which is considered to be indicative of moderate quality. The risk of bias in included case series studies was assessed according to the National Heart, Lung and Blood Institute Study Quality Assessment Tools and the results are presented in Table S3 [17] . The overall score was 52 of 63 (83%), which is considered to be indicative of satisfying quality. The pooled prevalence rates of all GBSs cases stratified amongst different included COVID-19 populations are presented in Figure 2 . Amongst COVID-19 patients in the community (including hospitalized and non-hospitalized cases), the pooled GBSs rate was 0.15‰ (95% CI 0%-0.49‰; three studies; I 2 = 96%; p for Cochran Q < 0.001; The results of all analyses regarding the secondary outcomes of interest (demographics, GBS subtypes, diagnostics, treatment and outcomes) are presented in Table 2 . The mean age at GBSs diagnosis was 58.9 ± 1.7 years amongst COVID-19 patients ( Figure S2a ). No mean age differences between COVID-19 patients and non-COVID-19 controls ( Figure S2b ) were identified. Additionally, male sex was more prevalent amongst COVID-19 GBSs cases (pooled rate 72.6%, 95% CI 64.5%-80.0%; 16 studies; I 2 = 97%; p for Cochran Q 0.362; Figure S3a ), but it was not related to COVID-19 status amongst GBSs cases (OR 1.58, 95% CI 0.79-3.19; five studies; I 2 = 0%; p for Cochran Q 0.521; Figure S3b ). Regarding the clinical characteristics of GBSs, amongst COVID-19 patients 41.4% (95% CI 23.5%-60.4%; seven studies; I 2 = 46%; p for Cochran Q 0.088; Figure S4a ) were reported to suffer from anosmia or ageusia, and SARS-CoV-2 infection was associated with increased odds for olfactory or gustatory dysfunction (OR 15.67, 95% CI 1.88-130.51; F I G U R E 1 Flow chart presenting the selection of eligible studies two studies; I 2 = 0%; p for Cochran Q 0.615; Figure S4b ) amongst GBSs cases. Additional cranial nerve involvement was also frequent amongst COVID-19 GBSs patients (pooled rate 42.8%, 95% CI 32.8%-53%; 12 studies; I 2 = 0%; p for Cochran Q 0.591; Figure S5 ). Finally, no association was observed between MFS and COVID-19 status (OR 1.58, 95% CI 0.31-8.07; four studies; I 2 = 0%; p for Cochran Q 0.976; Figure S6 ). Figure S8 ) and 18% (95% CI 2.7%-42.6%; seven studies; I 2 = 64%; p for Cochran Q 0.01; Figure S9) In the present systematic review and meta-analysis, an overall GBSs an estimated GBSs incidence of between 0.016 and 0.82 cases per 1000 COVID-19 infections [5] . At population level, the authors also noted that the absence of a significant increase in total GBSs cases during the pandemic might indicate a lack of 'causal' association between SARS-CoV-2 and GBSs, or might be attributed to the reduced transmission of common infective GBSs triggers following the implementation of lockdown and public hygiene measures [5] . Nonetheless, this epidemiological analysis included all GBSs cases irrespective of their SARS-COV-2 infection status and thus the reported incidence rates are not comparable to our results. Italy during the pandemic [25, 26] . Also, since GBSs incidence has been shown to be significantly higher in Italy compared to the rest of Europe both during the pre-COVID-19 and in the COVID-19 era F I G U R E 4 Pooled in-hospital mortality rate amongst COVID-19-associated Guillain−Barré syndrome spectrum cases, stratified by study design (a) and probability of in-hospital mortality amongst COVID-19-associated Guillain−Barré syndrome spectrum cases compared to contemporary or historical controls (b) [27] , it would be plausible to assume that genetic factors could confer a higher susceptibility of the Italian population to GBSs also in the setting of SARS-CoV-2 infection. Compared with occurrence rates of GBSs following infection with pathogens that have been 'causally' linked to GBSs, such as C. jejuni and CMV with corresponding occurrence rates between 0.25 to 0.65 and 0.6 to 2.2 GBSs per 1000 infections, respectively [28] , the results of the present meta-analysis suggest a weaker association between GBSs and SARS-CoV-2 infection. Although causality (or lack thereof) cannot be inferred by the available epidemiological evidence, there are no scientific accounts of a 'molecular mimicry' link between SARS-CoV-2 and GBSs to date [5] . In particular, SARS- CoV-2 appears to share no homology with human nerve axonal or myelin proteins and glycoproteins, at either the protein or the nucleic acid level. However, taking into consideration the high variability in genetic and biosynthetic pathways of human gangliosides, and the fact that new SARS-CoV-2 variants continue to emerge [29] , the extent to which 'molecular mimicry' might underlie GBSs manifestation in COVID-19 patients remains to be verified. In our meta-analysis, demyelinating GBSs was more frequently encountered amongst SARS-CoV-2-infected patients compared to their non-infected contemporary or historical GBSs counterparts. This observation is in line with the low prevalence of ganglioside antibodies amongst SARS-CoV-2 positive GBSs patients, and is also consistent with previous research that supports a stronger correlation of ganglioside antibodies with axonal rather than demyelinating GBSs variants [30] . Our findings also show that blood−brain barrier dysfunction was prevalent amongst GBSs COVID-19 cases (as indicated by the evidence of cytoalbuminologic dissociation); yet, no association was noted between SARS-CoV-2 infection status and blood−brain barrier dysfunction. In addition, no evidence of SARS-CoV-2 RNA was found in the CSF of SARS-CoV-2 positive GBSs patients, although scarce cases with positive PCR CSF findings have been reported previously [24] . Our findings of the predominance of the demyelinating variants of GBSs in COVID-19 patients, the satisfactory response to standard treatments (intravenous immunoglobulin or plasmapheresis) and the mainly good outcome upon hospital discharge have also been confirmed by another systematic review and individual participant data meta-analysis that has recently been published and included 61 patients derived by 45 case reports and case series studies [31] . Taken together, these results lend support to the hypothesis of a post-infectious GBSs aetiology, which suggests an immunemediated rather than a direct SARS-CoV-2-mediated cause of GBSs in COVID-19 patients [11] . Blood−brain barrier dysfunction and demyelinating disorders have been previously reported in conjunction with COVID-19 [32] and are also currently considered to reflect an aberrant, SARS-CoV-2-induced upsurge of pro-inflammatory cytokines in the setting of a COVID-19 cytokine storm [33] . Amongst the cytokines/chemokines implicated in the COVID-19 cytokine storm, tumour necrosis factor α, interleukin-1β (IL-1β), IL-6, IL-17 and interferonγ have been shown to hold a pivotal role also in GBSs propagation [33] . Modulation of cytokine function has thus been proposed as a therapeutic target for the management of both COVID-19 and GBSs. In accordance with previously published studies reporting the presence of olfactory or gustatory dysfunction in up to 75% of COVID-19 patients [34] [35] [36] , our meta-analysis revealed a highly sig- Thus, the generalizability of the present results warrants corroboration in larger population-based studies. Second, there were few studies providing estimates of the latency period between COVID-19 and GBSs, but significant discrepancies in the definition of latency period (e.g., based on first clinical symptoms, first diagnosis or clinical nadir) and the associated reported descriptive statistics were noted across studies [4, 5, 39] . Thus, these results could not be included in the aggregate metaanalysis. Previous systematic reviews of GBSs cases in the context of COVID-19, however, have shown that COVID-19 manifestations consistently precede GBSs symptoms (median interval 14 days, interquartile range 7-20) [1] and support further the hypothesis of a post-infectious GBSs aetiology [11] . Notably, the 2-week interval between SARS-CoV-2 infection and GBSs also coincides with the second phase of COVID-19, when the cytokine storm, the respiratory failure and the multiorgan dysfunction typically peak [40] . During this phase, in critically ill COVID-19 patients, GBSs may masquerade as critical illness polyneuropathy, and should always be considered when difficulty in weaning from mechanical ventilation is noted. In these cases, ancillary electrophysiological and CSF testing is typically required for an accurate differential diagnosis [41] . However, unless these cases come to the attention of a neurologist, GBSs may remain underdiagnosed in critically ill COVID-19 patients, possibly limiting the estimation of the prevalence and mortality rates mainly to non-severe COVID-19 cases. Furthermore, clinicians should also be aware that at least a third of SARS-CoV-2 patients may be asymptomatic [42] , further obscuring the diagnosis of post-COVID-19 GBSs and highlighting the need for SARS-CoV-2 screening in all GBSs cases during the pandemic. Third, due to the substantial heterogeneity in reported outcomes and patient populations of the included studies, our metaanalysis cannot yield evidence comparable to results of large-scale epidemiological studies. Nonetheless, as epidemiological data on COVID-19-associated GBSs are not currently available, the findings of the present meta-analysis are considered to be of high relevance, as they provide preliminary estimates of GBSs prevalence amongst the COVID-19 population. In the upcoming months, as COVID-19 vaccines become widely available, whilst COVID-19 continues to spread, estimates of GBSs prevalence for GBSs surveillance will be urgently needed [43] . To this end, experience gained from the 2009 H1N1 pandemic and the H1N1 vaccine safety surveillance programmes underlines the role of early monitoring of GBSs both in the vaccinated and unvaccinated populations [44] . In conclusion, the present systematic review and meta-analysis provides evidence of an overall GBSs prevalence of 0.15‰ amongst the COVID-19 population. Although an increased risk for GBSs was found in SARS-CoV-2-infected patients compared with contemporary or historical controls, our results suggest a weaker association of GBSs with SARS-CoV-2 compared to infective pathogens 'causally' related to GBSs. The findings of (i) predominantly demyelinating GBSs subtypes amongst COVID-19 patients, (ii) satisfactory GBSs response to immunomodulatory treatment and (iii) negative serological and CSF testing for ganglioside antibodies and SARS-CoV-2 RNA, respectively, indicate that GBSs most probably comprises another facet of autoimmunity in the setting of COVID-19. Further, international cohort studies are required to independently confirm these preliminary observations and provide additional insight on the potential cause−effect relationship between COVID-19 and GBSs. None. None. Guillain− Barré syndrome spectrum associated with COVID-19: an up-to-date systematic review of 73 cases Guillain−Barré syndrome associated with SARS-CoV-2 infection: causality or coincidence? Guillain−Barré syndrome in the COVID-19 era: just an occasional cluster? Guillain−Barré syndrome and COVID-19: an observational multicentre study from two Italian hotspot regions Epidemiological and cohort study finds no association between COVID-19 and Guillain−Barré syndrome The epidemiology of Guillain−Barré syndrome worldwide. A systematic literature review Guillain−Barré syndrome Atypical Bickerstaff brainstem encephalitis: ataxic hypersomnolence without ophthalmoplegia Population incidence of Guillain−Barré syndrome: a systematic review and metaanalysis Infectious and noninfectious triggers in Guillain− Barré syndrome Guillain−Barré syndrome: the first documented COVID-19-triggered autoimmune neurologic disease: more to come with myositis in the offing Guillain−Barré syndrome associated with Zika virus infection in Colombia Infectious origins of, and molecular mimicry in, Guillain− Barré and Fisher syndromes European Centre for Disease Prevention and Control. Case definition for coronavirus disease 2019 (COVID-19), as of 3 The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration Meta-analysis of observational studies in epidemiology: a proposal for reporting. Metaanalysis of Observational Studies in Epidemiology (MOOSE) group Study quality assessment tools The Newcastle−Ottawa Scale (NOS) for assessing the quality of nonrandomized studies in metaanalyses Meta-analysis in clinical trials Cochrane Handbook for Systematic Reviews of Interventions. The Cochrane Collaboration Bias in meta-analysis detected by a simple, graphical test Closing the gap between methodologists and end-users: R as a computational back-end Incidence, clinical, risk factors and outcomes of Guillain−Barré in COVID-19 Is social connectedness a risk factor for the spreading of COVID-19 among older adults? The Italian paradox ACE2 gene variants may underlie interindividual variability and susceptibility to COVID-19 in the Italian population Increased incidence of axonal Guillain−Barré syndrome in La Spezia area of Italy: a 13-year follow-up study Guillain−Barré syndrome Emergence of a highly fit SARS-CoV-2 variant Antiganglioside antibodies are associated with axonal Guillain−Barré syndrome: a Japanese−Italian collaborative study Guillain−Barré syndrome associated with SARS-CoV-2 infection: a systematic review and individual participant data meta-analysis Neurological manifestations and implications of COVID-19 pandemic Guillain−Barré syndrome and COVID-19: possible role of the cytokine storm Quantitative evaluation of olfactory dysfunction in hospitalized patients with coronavirus [2] (COVID-19) Olfactory bulb and mucosa abnormalities in persistent COVID-19-induced anosmia: a magnetic resonance imaging study The prevalence of olfactory and gustatory dysfunction in COVID-19 patients: a systematic review and meta-analysis Microvascular injury in the brains of patients with COVID-19 Neuropathology of patients with COVID-19 in Germany: a post-mortem case series COVID-19 provoking Guillain−Barré syndrome: the Bergamo case series COVID-19-associated acute respiratory distress syndrome (CARDS): current knowledge on pathophysiology and ICU treatment-a narrative review Distinctions between critical illness polyneuropathy and axonal Guillain−Barré syndrome The proportion of SARS-CoV-2 infections that are asymptomatic : a systematic review COVID-19 vaccine and Guillain−Barré syndrome: let's not leap to associations Guillain−Barré syndrome, influenza, and influenza vaccination: the epidemiologic evidence Cerebrospinal fluid findings in neurological diseases associated with COVID-19 and insights into mechanisms of disease development Immune-mediated neurological syndromes in SARS-CoV-2-infected patients Neurology of COVID-19 in Singapore Neurological associations of COVID-19-do we know enough: a tertiary care hospital based study Neurologic manifestations associated with COVID-19: a multicentre registry The emerging spectrum of COVID-19 neurology: clinical, radiological and laboratory findings Neurologic manifestations in hospitalized patients with COVID-19: the ALBACOVID registry Guillain−Barré syndrome as a parainfectious manifestation of SARS-CoV-2 infection: a case series COVID-19-related and not related Guillain−Barré syndromes share the same management pitfalls during lock down: the experience of Liguria region in Italy SARS-CoV-2 and Guillain− Barré syndrome: AIDP variant with a favourable outcome Clinical neurophysiology and cerebrospinal liquor analysis to detect Guillain−Barré syndrome and polyneuritis cranialis in COVID-19 patients: a case series COVID-19 associated Guillain− Barré syndrome: contrasting tale of four patients from a tertiary care centre in India Guillain−Barré syndrome associated with SARS-CoV-2 The data that support the findings of this study are available from the corresponding author upon reasonable request. Additional supporting information may be found online in the Supporting Information section.